Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap Up - Here's Why

Key Points

• Shares gapped up premarket, opening at $277.00 versus a prior close of $268.55 (about +3.1%) with only 101 shares traded.
• Attractive valuation and strong liquidity: market cap $7.48B, P/E 9.92, debt-to-equity 0.16, quick ratio 4.19 and current ratio 5.62, though the stock sits below its 200-day moving average of $295.27.
• Recent results and business profile: Q reported EPS $2.51 on $693.2M revenue with a 29.42% net margin; Bio‑Rad supplies instruments, consumables and reagent systems for life sciences and clinical diagnostics.

Bio-Rad Laboratories, Inc. (NYSE:BIO.B - Get Free Report) shares gapped up prior to trading on Tuesday . The stock had previously closed at $268.55, but opened at $277.00. Bio-Rad Laboratories shares last traded at $277.00, with a volume of 101 shares traded.

Bio-Rad Laboratories Stock Up 3.1%

The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.19 and a current ratio of 5.62. The company has a market cap of $7.48 billion, a price-to-earnings ratio of 9.92 and a beta of 0.98. The stock's fifty day moving average is $277.48 and its two-hundred day moving average is $295.27.

Bio-Rad Laboratories (NYSE:BIO.B - Get Free Report) last posted its earnings results on Thursday, February 12th. The company reported $2.51 earnings per share for the quarter. Bio-Rad Laboratories had a net margin of 29.42% and a return on equity of 3.86%. The company had revenue of $693.20 million for the quarter.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of innovative products and systems that serve the life science research and clinical diagnostics markets. The company operates through two primary segments: Life Science, which delivers instruments, consumables and software for research applications, and Clinical Diagnostics, which offers quality control materials and reagent systems for blood typing, immunology and molecular testing. Bio-Rad's product portfolio supports a wide range of applications, including protein analysis, gene expression, cell biology and digital PCR.

In the Life Science segment, Bio-Rad develops and markets technologies such as electrophoresis and imaging systems, chromatography instruments, laboratory consumables and software platforms that streamline experimental workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.